propafenone has been researched along with uk 68798 in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bauer, A; Becker, R; Busch, A; Freigang, KD; Gerlach, U; Hansen, A; Kraft, P; Kübler, W; Lang, HJ; Müller, M; Schöls, W; Senges, JC; Voss, F | 1 |
| Knobloch, K; Wirth, KJ | 1 |
| Droszcz, W; Graff, O; Kawecka-Jaszcz, K; Kozlowski, JW; Krzeminska-Pakula, M; Kulakowski, P; Malolepszy, J; Ruzyllo, W; Swiatecka, G; Szechinski, J; Tendera, M; Wnuk-Wojnar, AM | 1 |
| Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL | 1 |
| Kao, W; Kowey, PR; Winkel, E; Yan, GX | 1 |
| Bleich, M; Brendel, J; Busch, AE; Knobloch, K; Rosenstein, B; Wirth, KJ | 1 |
| Chandra, P; Danilo, P; Kim, HY; Lee, K; Rosen, MR; Rosen, TS; Yeom, ZH | 1 |
| Akhtar, M; Narayan, G; Sra, J | 1 |
| Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T | 1 |
| Eggertson, L | 1 |
| Baczkó, I; Benák, A; Hornyik, T; Husti, Z; Juhász, V; Nagy, N; Pap, R; Sághy, L; Varró, A; Virág, L | 1 |
3 review(s) available for propafenone and uk 68798
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Trials as Topic; Europe; Flecainide; Heart Conduction System; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Phenethylamines; Propafenone; Quinidine; Sotalol; Sulfonamides; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; United States | 2003 |
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablation; Flecainide; Heart Rate; Humans; Phenethylamines; Practice Guidelines as Topic; Propafenone; Quinidine; Stroke; Sulfonamides; Ventricular Dysfunction, Left | 2003 |
2 trial(s) available for propafenone and uk 68798
| Article | Year |
|---|---|
Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenethylamines; Propafenone; Proportional Hazards Models; Sulfonamides; Survival Analysis; Tachycardia, Supraventricular; Treatment Outcome | 2001 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Drug Monitoring; Female; Flecainide; Follow-Up Studies; Humans; Inpatients; Long QT Syndrome; Male; Middle Aged; Phenethylamines; Propafenone; Recurrence; Sotalol; Sulfonamides; Tachycardia, Ventricular; Treatment Outcome; Ventricular Function, Left; Withholding Treatment | 2007 |
14 other study(ies) available for propafenone and uk 68798
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Rate- and site-dependent effects of propafenone, dofetilide, and the new I(Ks)-blocking agent chromanol 293b on individual muscle layers of the intact canine heart.
Topics: Animals; Anti-Arrhythmia Agents; Chromans; Dogs; Heart; Phenethylamines; Potassium Channel Blockers; Propafenone; Refractory Period, Electrophysiological; Sulfonamides | 1999 |
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, Left; Atrial Function, Right; Flecainide; Male; Phenethylamines; Propafenone; Sulfonamides; Swine | 2001 |
Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Function; Atropine; Biphenyl Compounds; Chromans; Flecainide; Heart Atria; Hydantoins; Imidazoles; Imidazolidines; Male; Phenethylamines; Piperazines; Potassium Channel Blockers; Potassium Channels; Propafenone; Propanolamines; Sotalol; Sulfonamides; Swine; Ventricular Function | 2004 |
Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Heart Atria; Heart Ventricles; Phenethylamines; Potassium Channel Blockers; Propafenone; Random Allocation; Sodium Channel Blockers; Sulfonamides | 2004 |
Combined use of 1C and III agents for highly symptomatic, refractory atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Combinations; Female; Flecainide; Humans; Male; Middle Aged; Phenethylamines; Propafenone; Secondary Prevention; Sotalol; Sulfonamides; Treatment Failure; Treatment Outcome | 2006 |
Three heart medications in short supply in Canada.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Flecainide; Humans; Phenethylamines; Propafenone; Sulfonamides | 2014 |
Comparison of the effects of I
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Remodeling; Bee Venoms; Consciousness; Dogs; Electrocardiography; Heart Atria; Male; Phenethylamines; Potassium Channel Blockers; Potassium Channels; Propafenone; Receptors, Cholinergic; Refractory Period, Electrophysiological; Sulfonamides | 2018 |